Table 7

 Familial adenomatous polyposis patients treated with sulindac, celecoxib, or refecoxib for duodenal adenomas

AuthorTreatment
>(dose/day)
Type of studyDurationPatientsOutcomeSide effects
*The control group was treated with calcium and calciferol.
†The control group was treated with ursodeoxycholic acid.
NSAID, non-steroidal anti-inflammatory drug.
Nugent64,
>Debinski65
Sulindac
>400 mg
Randomised controlled clinical trial6 months11Number of polyps ↓ in 5 patients (p = 0.12 v placebo). Second evaluation: effect on small polyps (⩽2mm) (p = 0.02)1 patient with indigestion
Seow-Choen66*Sulindac
>300 mg
Randomised controlled clinical trial6 months15No effectNo adverse events reported
Richard67Sulindac
>300 mg
Clinical trial10–24 months5No regression of small residual polyps. 3 patients developed large polyps; 1 breakthrough carcinoma2 patients with abdominal cramp. 1 patient with upper GI bleeding
Phillips68Celecoxib
>800 mg
Randomised controlled clinical trial6 months30Number of polyps ↓ compared to placebo (p = 0.03)1 patient with allergic reaction. 1 patient with symptoms of dyspepsia
Winde69Sulindac
>50–300 supp dose
>reduction
Prospective, controlled, non-randomised phase II dose finding studyUp to 4 yearsxxNo effect on upper GI polyps2 patients with mild gastritis due to NSAID
Maclean70Refecoxib
>25 mg
Randomised controlled clinical trial6 months6Improvement in 2 patients with stage III polyposis; no effect in 4 patients; no effect in ursodeoxycholic acid group
Parker71Sulindac
>300 mg
Case report1No recurrence of duodenal polyps
Theodore72Sulindac
>300–400 mg
Case reports5 and 14 years2Sulindac normalised adenomatous ampulla and induced elimination of moderate dysplasia
Waddell73Sulindac
>300–400 mg
Case reports4.5–5 years2No effect on gastric and small intestinal polyps